-NEURIM PHARMACEUTICALS RECIBE LA AUTORIZACIÓN DE COMERCIALIZACIÓN EUROPEA PARA MELATONINA PEDIÁTRICA DE LIBERACIÓN PROLONGADA (SLENYTO®) EN EL TRATAMIENTO DEL INSOMNIO EN NIÑOS CON TRASTORNO POR DÉFICIT DE ATENCIÓN E HIPERACTIVIDAD (TDAH) TEL AVIV, Israel, 26 de marzo de 2025…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.